1. Dubois, Sydney, Jardin, et al: Novel molecular classifications of DLBCL. Nature Reviews Clinical Oncology 2018; 15:474-476 doi:10.1038/s41571-018-0041-z
2. Swerdlow SH, Campo E,Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). Lyon: IARC 2008; 4:88-93
3. Miao Y, Medeiros LJ, Li Y, et al: Genetic alterations and their clinical implications in DLBCL. Nature Reviews Clinical Oncology 2019; 16:634-652 doi:10.1038/s41571-019-0225-1
4. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74 doi:10.1038/nm0102-68
5. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences 2003; 100:9991-9996 doi:doi:10.1073/pnas.1732008100
6. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511 doi:10.1038/35000501
7. Coiffier B,Sarkozy C: Diffuse large B-cell lymphoma: R-CHOP failure--what to do? Hematology Am Soc Hematol Educ Program 2016; 366-378 doi:10.1182/asheducation-2016.1.366
8. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expressionprofiling. Nature 2000; 403:503 doi:10.1038/35000501.
9. Gascoyne, R. D, Kasbekar, et al: Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The new england journal o f medicine, 2018; 378:1396-1407 doi:10.1056/NEJMoa1801445
10. Huang HQ: Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma——A Study by the Groupe d'Etude des Lymphoma de l'Adulte. The Journal of Evidence-Based Medicine 2007; 7:23-25 doi:10.3969/j.issn.1671-5144.2007.01.009
11. Pfreundschuh M: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006; 7:379-391 doi:10.1016/S1470-2045(06)70664-7
12. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology 2008; 9:105-116 doi:10.1016/S1470-2045(08)70002-0
13. Wu Z, Guan Q, Han X, et al: A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma. Aging 13:22947-22962 doi:10.18632/aging.203587
14. Feng P, Li H, Pei J, et al: Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL). Frontiers in Genetics 2021; 12:1-7 doi:10.3389/fgene.2021.625414
15. Wang X, Hong Y, Meng S, et al: A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. Clinical Immunology 2022; 243:109105 doi:https://doi.org/10.1016/j.clim.2022.109105
16. Wang X, Lu Y, Liu Z, et al: A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma. Frontiers in Immunology 2022; 13:doi:10.3389/fimmu.2022.813031
17. Beheshti A, Stevenson K, Vanderburg C, et al: Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Scientific Reports 2019; 9:17161 doi:10.1038/s41598-019-52985-x
18. Sun X, Wang M, Wang M, et al: Metabolic Reprogramming in Triple-Negative Breast Cancer. Frontiers in Oncology 2020; 10:doi:10.3389/fonc.2020.00428
19. Liu B,Zhang X: Metabolic Reprogramming Underlying Brain Metastasis of Breast Cancer. Frontiers in Molecular Biosciences 2022; 8:doi:10.3389/fmolb.2021.791927
20. Xia L, Oyang L, Lin J, et al: The cancer metabolic reprogramming and immune response. Molecular Cancer 2021; 20:28 doi:10.1186/s12943-021-01316-8
21. Liu J, Zhou G, Wang X, et al: Metabolic reprogramming consequences of sepsis: adaptations and contradictions. Cellular and Molecular Life Sciences 2022; 79:456 doi:10.1007/s00018-022-04490-0
22. He L, Chen J, Xu F, et al: Prognostic Implication of a Metabolism-Associated Gene Signature in Lung Adenocarcinoma. Molecular Therapy — Oncolytics 2020; 19:265-277 doi:10.1016/j.omto.2020.09.011
23. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88-92 doi:10.1038/nature08638
24. Schwartz RS, Lenz G,Staudt LM: Aggressive lymphomas. N Engl J Med 2010; 362:1417-1429 doi:10.1056/NEJMra0807082
25. Natarajan SK,Venneti S: Glutamine Metabolism in Brain Tumors. Cancers 2019; 11:1628
26. Choi Y-K,Park K-G: Targeting Glutamine Metabolism for Cancer Treatment. Biomolecules & Therapeutics 2018; 26:19-28 doi:10.4062/biomolther.2017.178
27. Ma G, Zhang Z, Li P, et al: Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Communication and Signaling 2022; 20:114 doi:10.1186/s12964-022-00909-0
28. Heiden MV,Deberardinis RJ: Understanding the Intersections between Metabolism and Cancer Biology. Cell 2017; 168:657-669 doi:10.1016/j.cell.2016.12.039
29. Stelzer G, Rosen N, Plaschkes I, et al: The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current Protocols in Bioinformatics 2016; 54:1.30.31-31.30.33 doi:https://doi.org/10.1002/cpbi.5
30. Safran M, Rosen N, Twik M, et al: The GeneCards Suite, in Practical Guide to Life Science Databases. Edited by Abugessaisa I,Kasukawa T. Singapore, Springer Nature Singapore, 2021, pp 27-56
31. Runne H, Kuhn A, Wild EJ, et al: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A 2007; 104:14424-14429 doi:10.1073/pnas.0703652104
32. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105:13520-13525 doi:10.1073/pnas.0804295105
33. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313-2323 doi:10.1056/NEJMoa0802885
34. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al: High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011; 96:996-1001 doi:10.3324/haematol.2010.037408
35. Barrans SL, Crouch S, Care MA, et al: Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol 2012; 159:441-453 doi:10.1111/bjh.12045
36. Scott DW, Wright GW, Williams PM, et al: Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214-1217 doi:10.1182/blood-2013-11-536433
37. Care MA, Cocco M, Laye JP, et al: SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Res 2014; 42:7591-7610 doi:10.1093/nar/gku451
38. Ta R, Santini C, Gou P, et al: Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. J Mol Diagn 2021; 23:323-340 doi:10.1016/j.jmoldx.2020.11.013
39. Gautier L, Cope L, Bolstad BM, et al: affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;
40. Ritchie ME, Belinda P, Wu D, et al: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research 2015; 43:e47
41. Zhu J, Liu Y, Ao H, et al: Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer. Frontiers in Oncology 2020; 10:doi:10.3389/fonc.2020.01132
42. Yang W, Soares J, Greninger P, et al: Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research 2012; 41:D955-D961 doi:10.1093/nar/gks1111
43. Wilkerson MD,Hayes DN: ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010; 26:1572-1573 doi:10.1093/bioinformatics/btq170
44. Xue J, Lee C, Wakeham SG, et al: Using principal components analysis (PCA) with cluster analysis to study the organic geochemistry of sinking particles in the ocean. Organic Geochemistry 2011; 42:356-367 doi:10.1016/j.orggeochem.2011.01.012
45. Dunn PJ, Thomson E, Campbell J, et al: ImmPort: Shared research data for bioinformatics and immunology, 2015
46. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105:1851-1861 doi:10.1182/blood-2004-07-2947
47. Yuan Y, Ni S, Zhuge A, et al: Iron Regulates the Warburg Effect and Ferroptosis in Colorectal Cancer. Frontiers in Oncology 2021; 11:doi:10.3389/fonc.2021.614778
48. Fu R, Yang P, Amin S, et al: A novel miR-206/hnRNPA1/PKM2 axis reshapes the Warburg effect to suppress colon cancer growth. Biochemical and Biophysical Research Communications 2020; 531:465-471 doi:https://doi.org/10.1016/j.bbrc.2020.08.019
49. Zhang S, Pei M, Li Z, et al: Double-negative feedback interaction between DNA methyltransferase 3A and microRNA-145 in the Warburg effect of ovarian cancer cells. Cancer Science 2018; 109:2734-2745 doi:https://doi.org/10.1111/cas.13734
50. Kaddis NE-S: Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma. Blood 2016; 128:5420-5420 doi:10.1182/blood.V128.22.5420.5420
51. Painschab MS, Kasonkanji E, Zuze T, et al: Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort. British Journal of Haematology 2019; 184:364-372 doi:https://doi.org/10.1111/bjh.15625
52. Pontoizeau C, Girard A, Mesbah H, et al: Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome. Clinical Nuclear Medicine 2020; 45:118-122 doi:10.1097/rlu.0000000000002879
53. Vieira I, Quintela M, Moreira C, et al: The Magnitude of Lactate Dehydrogenase Elevation As a Predictive Factor for Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma. Blood 2019; 134:5342-5342
54. Noble RA, Thomas H, Zhao Y, et al: Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. British Journal of Cancer 2022; 127:937-947 doi:10.1038/s41416-022-01848-w
55. Halford SER, Walter H, McKay P, et al: Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Journal of Clinical Oncology 2021; 39:3115-3115 doi:10.1200/JCO.2021.39.15_suppl.3115
56. Ohi N, Okuno M, Tanaka H, et al: Combination Therapy Strategy for Lymphoma Based on Cancer Energy Metabolism of OPB-111077, a Novel Antitumor Agent Inhibiting Mitochondrial Oxidative Phosphorylation. Blood 2021; 138:4363-4363 doi:10.1182/blood-2021-148979
57. Gu J, Yanamadala V,Czuczman MS: Metformin Lowers The Mitochondrial Potential Of Lymphoma Cells and Its Use During Front-Line Rituximab-Based Chemo-Immunotherapy Improves The Clinical Outcome Of Diffuse Large B-Cell Lymphoma. Blood 2013; 122:1825-1825
58. Zhang Y, Zhang R, Liang F, et al: Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model. Frontiers in Oncology 2020; 10:1-17 doi:10.3389/fonc.2020.598801
59. Wu X, Yao Y, Li Z, et al: Identification of a Transcriptional Prognostic Signature From Five Metabolic Pathways in Oral Squamous Cell Carcinoma. Frontiers in Oncology 2020; 10:doi:10.3389/fonc.2020.572919
60. Lou I, Odorico S, Yu XM, et al: Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer. Surgery 2017; 163 doi:10.1016/j.surg.2017.07.039
61. Pachynski RK, Wang P, Salazar N, et al: Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment. Frontiers in Immunology 2019; 10:doi:10.3389/fimmu.2019.00983
62. Wang Z, Dahiya S, Provencher H, et al: The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clinical Cancer Research 2007; 13:6327-6334 doi:10.1158/1078-0432.CCR-07-0310
63. Lv M, Zhang S, Dong Y, et al: PolG Inhibits Gastric Cancer Glycolysis and Viability by Suppressing PKM2 Phosphorylation. Cancer Management and Research 2021; 13:1559-1570 doi:10.2147/CMAR.S292306
64. Zhaoxia L, Rongna Y, Xiaolin Y, et al: Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. Mediators of Inflammation 2016; 2016:1-6 doi:10.1155/2016/5953498
65. Schmidt A,Hall MN: Signaling to the actin cytoskeleton. Annual review of cell and developmental biology 1998; 14:305-338 doi:10.1146/annurev.cellbio.14.1.305
66. Guannan, Zhou, Zhongyi, et al: Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growth in vivo, and migration of OCCC cells in vitro, by down-regulating the PI3K/AKT and actin cytoskeleton signaling pathways. American journal of translational research 2019; 11:6290-6303
67. Pappa KI, Lygirou V, Kontostathi G, et al: Proteomic Analysis of Normal and Cancer Cervical Cell Lines Reveals Deregulation of Cytoskeleton-associated Proteins. Cancer Genomics & Proteomics 2017; 14:253-266 doi:10.21873/cgp.20036
68. Sousa CM, Biancur DE, Wang X, et al: Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 2016; 536:479-483 doi:10.1038/nature19084
69. Parker SJ, Amendola CR, Hollinshead K, et al: Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer. Cancer Discovery 2020; 10:doi:10.1158/2159-8290.CD-19-0959
70. Katia, Aquilano, Sara, et al: Glutathione: new roles in redox signaling for an old antioxidant. Frontiers in Pharmacology 2014; 5:196 doi:10.3389/fphar.2014.00196
71. Andrea, Scirè, Laura, et al: Glutathione compartmentalization and its role in glutathionylation and other regulatory processes of cellular pathways. Biofactors 2018; 152-168 doi:10.1002/biof.1476
72. Wang H, Cheng Y, Mao C, et al: Emerging mechanisms and targeted therapy of ferroptosis in cancer. Molecular Therapy 2021; 29:doi:10.1016/j.ymthe.2021.03.022
73. Chen X, Kang R, Kroemer G, et al: Ferroptosis in infection, inflammation, and immunity. Journal of Experimental Medicine 2021; 218:doi:10.1084/jem.20210518
74. Gao J, Luo T,Wang J: Gene interfered-ferroptosis therapy for cancers. Nature Communications 2021; 5311 doi:10.1038/s41467-021-25632-1
75. Espinosa-Diez C, Miguel V MD, Kietzmann T, et al: Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 2015; 6:183-197 doi:10.1016/j.redox.2015.07.008
76. Jagust P, Alcala S, Jr BS, et al: Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. World Journal of Stem Cells 2020; 12:1410-1428 doi:10.4252/wjsc.v12.i11.1410
77. Gamcsik MP, Kasibhatla MS, Teeter SD, et al: Glutathione levels in human tumors. Biomarkers 2012; 17:671-691 doi:10.3109/1354750X.2012.715672
78. Peng L, Linghu R, Chen D, et al: Inhibition of glutathione metabolism attenuates esophageal cancer progression. Experimental & Molecular Medicine 2017; 49:e318 doi:10.1038/emm.2017.15
79. Simon, Schwörer, Santosha A, et al: Cancer Metabolism Drives a Stromal Regenerative Response. Cell metabolism 2019; 29:576-591 doi:10.1016/j.cmet.2019.01.015
80. Bian Y, Li W, Daniel M Kremer PS, et al: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 2020; 585:277-282 doi:10.1038/s41586-020-2682-1
81. Horst AK,Wagener C: Bitter Sweetness of Complexity. Topics in Current Chemistry 2009; 288:1-15 doi:10.1007/128_2008_8
82. Vad-Nielsen J, Jakobsen KR, Daugaard TF, et al: Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1α down-regulation in metastatic cells. Bmc Cancer 2016; 16:1-21 doi:10.1186/s12885-016-2059-x
83. Yong SA, Xw B,Xb A: LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5. Brain Research Bulletin 2021; 176:121-129 doi:10.1016/j.brainresbull.2021.07.009
84. Zhu Y, Pu Z, Li Z, et al: Comprehensive Analysis of the Expression and Prognosis Value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology 2021; 11:700528 doi:10.3389/fonc.2021.700528
85. Ruggeri L, Mancusi A, Perruccio K, et al: Natural killer cell alloreactivity for leukemia therapy. Journal of Immunotherapy 2005; 28:175-182 doi:10.1097/01.cji.0000161395.88959.1f
86. Fridman WH, Pagès F, Sautès-Fridman C, et al: The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer 2012; 12:298-306 doi:10.1038/nrc3245